Reprieve Cardiovascular reveals late-breaking AHF clinical trial data
Category: #healthcare  By Mateen Dalal  Date: 2019-05-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Reprieve Cardiovascular reveals late-breaking AHF clinical trial data

The trials were set to determine the Reprieve-Guided Diuretic Therapy system’s ability to achieve safe net volume reduction while alleviating related symptoms in ADHF patients.

Reprieve Cardiovascular™, one of the leading medical device company has recently announced results of its two prospective, non-randomized clinical trials in patients hospitalized with Acute Heart Failure (AHF). According to reports, the two studies demonstrate that the use of Reprieve-Guided Diuretic Therapy enabled safer decongestion for patients with AHF.

Reportedly, the 19 patients from the TARGET-1 & TARGET-2 trials were set to determine whether the Reprieve-Guided Diuretic Therapy system could attain safe net volume reduction while extensively alleviating related symptoms in ADHF patients. The data reported a significant rise in diuresis, net negative fluid balance, enhanced kidney function and improvement in clinical symptoms, cite reports.

Claiming the therapy to be safe and effective, Prof. Piotr Ponikowski, Professor of Cardiology, Wroclaw Medical University, Poland, said Reprieve’s automated fluid management technology offered faster, more controlled fluid removal while securing AHF patients from a severe drop in blood pressure. The therapy maintained ideal intravascular fluid volume along with renal perfusion and cardiac output, he said.

As per Jim Dillon, President & CEO, Reprieve Cardiovascular, the results supported the firm’s continued efforts to evaluate the impact of its therapy on alleviating the pain points that complicate care of patients with acute heart failure which includes long hospital stays and eventually poor patient prognosis.

For the record, ADHF is an advent of heart failure symptoms, which mainly include swelling in the extremities, difficulty breathing (dyspnea), and fatigue. The signs and symptoms of fluid overload are said to be responsible for about 90% of heart failure hospital admissions.

Nevertheless, Reprieve Cardiovascular’s Guided Diuretic Therapy has the potential to enable precise and predictable management of a patient’s fluid levels, protecting them against dangerous fluid imbalances and offering better control over diuretic therapy, thereby increasing diuretic efficiency.

Reportedly, the therapy’s potential benefits include faster decongestion while protecting core organ functions, lowering symptoms of congestive heart failure like ascites, shortness of breath, and swelling, reduced time in hospital and readmission rates, and a better quality of living for patients.

Source Credit: https://www.apnews.com/Business%20Wire/d37ac798996249bcb727f6e65c7fbc87

https://www.businesswire.com/news/home/20190524005337/en/Reprieve-Cardiovascular-Announces-Late-Breaking-Acute-Heart-Failure

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
By Mateen Dalal

Shionogi & Co., Ltd., a Japan-based pharmaceutical company recently announced approval of drug c...

Disney stock soars as Disney+ reaches 10 million sign ups on day 1
Disney stock soars as Disney+ reaches 10 million sign ups on day 1
By Mateen Dalal

Reports confirm that Walt Disney Co shares climbed to a record high after the entertainment company ...

China’s Xpeng Motors secures $400m to expand electric car production
China’s Xpeng Motors secures $400m to expand electric car production
By Mateen Dalal

  Xpeng has already launched vehicles like G3 SUV and P7 sedan Xpeng and investors like Xia...